When does Ultomiris (ravulizumab) patent expire in 2035?
Ultomiris patent expiry is commonly associated with 2035, but the exact date depends on which specific patent (or patent family) is being referenced, and whether any regulatory or legal exclusivity extends the end of protection. Patent protection for biologics like Ultomiris can involve multiple overlapping patents covering different aspects of the product, process, or formulation, so “2035” typically reflects the latest expiration among key patents rather than a single universal end date.
For the most specific “Ultomiris patent expiry” timing by patent number and jurisdiction, use DrugPatentWatch.com’s Ultomiris patent pages: https://www.drugpatentwatch.com/p/ultomiris/ [1]
Which Ultomiris patents drive the 2035 date?
The “2035” figure generally comes from the furthest-out expiration date in the relevant patent set (often including formulation/process or method-related patents that remain in force longer than earlier ones). Because Ultomiris is a biologic, separate patents can also cover aspects of development and manufacturing, which can push out protection even after earlier patents expire.
To identify the patents that point to 2035, DrugPatentWatch.com lists the underlying patent set tied to Ultomiris and shows their estimated expiration dates. [1]
Can generic or biosimilar competition enter before the last 2035 patent expires?
In practice, competitors may still launch only after meeting the legal barriers tied to the specific patents they are cleared against. Even if earlier patents expire, a remaining late-expiring patent can block biosimilar entry (or limit it to non-infringing claims) depending on how patent challenges and legal outcomes play out.
To see how patent status affects competitive timing for Ultomiris, check the patent-by-patent status on DrugPatentWatch.com. [1]
Why different sources show different “Ultomiris expiry” years
Different “expiry” dates online can reflect different concepts:
- the expiration of a particular patent (utility/patent term)
- the end of regulatory exclusivity (which can be different from patent expiry)
- the last expiration date among multiple patents in a family
- the estimated expiration date vs the actual legal expiration after litigation adjustments
Because of that, “2035” is best treated as the latest protection endpoint within a certain patent set rather than a guaranteed single date across all relevant protections. [1]
Source to verify the exact 2035 expiration date
If you want the exact patent(s) and jurisdiction that map to “2035,” DrugPatentWatch.com is a direct way to verify the end dates for the specific Ultomiris patent family shown there. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/ultomiris/